logo BDSP

Base documentaire

  1. The contribution of the case-control approach to vaccine evaluation : Pneumococcal and Haemophilus influenzae type B PRP vaccines.

    Article - En anglais

    Case-control studies have had an increasing role in the postlicensure evaluation of vaccine efficacy.

    We review the contribution of case-control studies to the evaluation of vaccines for Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib) and compare these studies with clinical trials of these vaccines.

    We located one clinical trial and eight case-control studies of Hib PRP vaccine efficacy and three clinical trials and four case-control studies of pneumococcal vaccine efficacy.

    The pooled estimate of Hib PRP vaccine efficacy based on the case-control studies (0.38,95% CL=0.15-0.55) was lower than the efficacy of the clinical trial conducted in Finland (0.8,95% CL=0.57-0.98).

    The pooled estimate of pneumococcal vaccine efficacy based on the case-control studies (0.56,95% CL=0.44-0.66) was also lower than the pooled efficacy of the South African clinical trials (0.79,95% CL=0.69-0.86).

    Although the clinical trials provided crucial evidence that these vaccines worked in selected international settings, the direct evidence of efficacy in the United States rests largely on the case-control results.

    The utility of the case-control approach is supported.

    Mots-clés Pascal : Evaluation, Efficacité, Vaccin, Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bactérie, Haemophilus influenzae, Pasteurellaceae, Etude comparative, Essai clinique, Méthodologie, Homme, Prévention, Etude cas témoin

    Mots-clés Pascal anglais : Evaluation, Efficiency, Vaccine, Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bacteria, Haemophilus influenzae, Pasteurellaceae, Comparative study, Clinical trial, Methodology, Human, Prevention, Case control study

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0407425

    Code Inist : 002B30A01C. Création : 10/04/1997.